Interactive Savings Map - Find out how much your state saved from generic and biosimilar medicines.

AAM Announces 2022 Board of Directors

WASHINGTON, DC (February 14, 2022) — The Association for Accessible Medicines (AAM) announced the election of its 2022 Board of Directors and Officers today.

Chirag Patel, President and Co-Chief Executive Officer, Amneal Pharmaceuticals Inc. is the 2022 AAM Chair of the Board. AAM also named Christine Baeder, Senior Vice President, Chief Operating Officer for US Generics, Teva Pharmaceuticals USA, Inc., Vice Chair of the Board and Terry Fullem, President, Jubilant Cadista Pharmaceuticals, Inc., as Treasurer.

Generic drugs saved the U.S. health system $338 billion in 2020, according to AAM's Generic Drug Access & Savings in the U.S. report.

The 2022 AAM Board of Directors includes:

  • Accord Healthcare, Inc.
Jeff Hampton, President
  • Ajanta Pharma USA Inc.
Jeff Burd, President
  • American Regent
Paul Diolosa, President and CEO
  • Amneal Pharmaceuticals Inc.
Chirag Patel, President and Co-Chief Executive Officer
  • Amphastar Pharmaceuticals, Inc.
Dan Dischner, Vice President, Corporate Communications
  • Apotex Corp.
Peter Hardwick, U.S. President and CEO
  • Aurobindo Pharma USA, Inc.
Paul McMahon, Senior Vice President, Commercial Operations
  • Cipla USA
Arunesh Verma, Chief Executive Officer
  • Dr. Reddy's Laboratories, Inc.
Vanessa Brill, Vice President Legal and Compliance, Americas
  • Fresenius Kabi USA
John Ducker, President and Chief Executive Officer
  • Glenmark Pharmaceuticals, Inc. USA
Sanjeev Krishan, President, North America
  • Hikma Pharmaceuticals USA
Brian Hoffmann, President of US Generics
  • Jubilant Cadista Pharmaceuticals, Inc.
Terry Fullem, President
  • Lupin Inc.
Alok Sonig, CEO, US Generics and Global Head - Generics R&D & Biosimilars
  • Mayne Pharma Group Limited
Hem Pandya, Senior Vice President, Head of Generic Products Division
  • Rhodes Pharmaceuticals L.P.
Vincent Mancinelli II, President
  • Sagent Pharmaceuticals
Dr. Peter Kaemmerer, Chief Executive Officer
  • Sandoz Inc., A Novartis Division
Keren Haruvi, President of Sandoz US and Head of North America
  • Sun Pharmaceutical Industries, Inc. (together with its subsidiary Taro Pharmaceuticals USA, Inc.)
Abhay Gandhi, CEO, North America
  • Teva Pharmaceuticals USA, Inc.
Christine Baeder, Senior Vice President, Chief Operating Officer for US Generics
  • Zydus Pharmaceuticals USA, Inc.
Crystal Fisher, Vice President, General Counsel and Compliance Officer

A complete list of 2022 AAM Members can be found here and learn more about each board member here.


Rachel Schwartz


About AAM

AAM is driven by the belief that access to safe, quality, effective medicine has a tremendous impact on a person’s life and the world around them. Generic and biosimilar medicines improve people’s lives, improving society and the economy in turn. AAM represents the manufacturers and distributors of finished generic pharmaceuticals and biosimilars, manufacturers and distributors of bulk pharmaceutical chemicals, and suppliers of other goods and services to the generic industry. Generic pharmaceuticals are 90 percent of prescriptions dispensed in the U.S. but only 18 percent of total drug spending.

About the Biosimilars Council

The Biosimilars Council, a division of the Association for Accessible Medicines (AAM), works to ensure a positive environment for patient access to biosimilar medicines. The Biosimilars Council is a leading source for information about the safety and efficacy of more affordable alternatives to costly brand biologic medicines. Areas of focus include public and health expert education, strategic partnerships, government affairs, legal affairs and regulatory policy. More information is available at

Association for Accessible Medicines


Sign-up for Updates

Receive relevant industry news, event information and the latest resources on biosimilars and generic medicines.

Stay Connected

For the latest updates, follow us on social media.